The Tuberculosis Drug Accelerator at year 10: what have we learned?

Bree B. Aldridge; David Barros-Aguirre; Clifton E. Barry; Robert H. Bates; Steven J. Berthel; Helena I. Boshoff; Kelly Chibale; Xin-Jie Chu; Christopher B. Cooper; Véronique Dartois; Ken Duncan; Nader Fotouhi; Fabian Gusovsky; Philip A. Hipskind; Dale J. Kempf; Joël Lelièvre; Anne J. Lenaerts; Case W. McNamara; Valerie Mizrahi; Carl Nathan; David B. Olsen; Tanya Parish; H. Michael Petrassi; Alexander Pym; Kyu Y. Rhee; Gregory T. Robertson; Jeremy Michael Rock; Eric J. Rubin; Betsy Russell; David G. Russell; James C. Sacchettini; Dirk Schnappinger; Michael Schrimpf; Anna M. Upton; Peter Warner; Paul Graham Wyatt; Ying Yuan

doi:10.1038/s41591-021-01442-2

The Tuberculosis Drug Accelerator at year 10: what have we learned?

Bree B. Aldridge, David Barros-Aguirre, Clifton E. Barry, Robert H. Bates, Steven J. Berthel, Helena I. Boshoff, Kelly Chibale, Xin-Jie Chu, Christopher B. Cooper, Véronique Dartois, Ken Duncan, Nader Fotouhi, Fabian Gusovsky, Philip A. Hipskind, Dale J. Kempf, Joël Lelièvre, Anne J. Lenaerts, Case W. McNamara, Valerie Mizrahi, Carl Nathan (Lead / Corresponding author)David B. Olsen, Tanya Parish, H. Michael Petrassi, Alexander Pym, Kyu Y. Rhee, Gregory T. Robertson, Jeremy Michael Rock, Eric J. Rubin, Betsy Russell, David G. Russell, James C. Sacchettini, Dirk Schnappinger, Michael Schrimpf, Anna M. Upton, Peter Warner, Paul Graham Wyatt, Ying Yuan

Drug Discovery Unit

Research output: Contribution to journal › Comment/debate › peer-review

15 Citations (Scopus)

Abstract

The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for the application of similar models to other diseases.

Original language	English
Pages (from-to)	1333-1337
Number of pages	5
Journal	Nature Medicine
Volume	27
Early online date	5 Jul 2021
DOIs	https://doi.org/10.1038/s41591-021-01442-2
Publication status	Published - Aug 2021

Keywords

Bacterial infection
Drug development
Drug screening
Intellectual-property rights
Research management

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41591-021-01442-2

Cite this

Aldridge, B. B., Barros-Aguirre, D., Barry, C. E., Bates, R. H., Berthel, S. J., Boshoff, H. I., Chibale, K., Chu, X-J., Cooper, C. B., Dartois, V., Duncan, K., Fotouhi, N., Gusovsky, F., Hipskind, P. A., Kempf, D. J., Lelièvre, J., Lenaerts, A. J., McNamara, C. W., Mizrahi, V., ... Yuan, Y. (2021). The Tuberculosis Drug Accelerator at year 10: what have we learned? Nature Medicine, 27, 1333-1337. https://doi.org/10.1038/s41591-021-01442-2

@article{efcc9bd821234f53a60f2e3e183a156b,

title = "The Tuberculosis Drug Accelerator at year 10: what have we learned?",

abstract = "The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. We review the consortium{\textquoteright}s achievements, advantages and limitations and advocate for the application of similar models to other diseases.",

keywords = "Bacterial infection, Drug development, Drug screening, Intellectual-property rights, Research management",

author = "Aldridge, {Bree B.} and David Barros-Aguirre and Barry, {Clifton E.} and Bates, {Robert H.} and Berthel, {Steven J.} and Boshoff, {Helena I.} and Kelly Chibale and Xin-Jie Chu and Cooper, {Christopher B.} and V{\'e}ronique Dartois and Ken Duncan and Nader Fotouhi and Fabian Gusovsky and Hipskind, {Philip A.} and Kempf, {Dale J.} and Jo{\"e}l Leli{\`e}vre and Lenaerts, {Anne J.} and McNamara, {Case W.} and Valerie Mizrahi and Carl Nathan and Olsen, {David B.} and Tanya Parish and Petrassi, {H. Michael} and Alexander Pym and Rhee, {Kyu Y.} and Robertson, {Gregory T.} and Rock, {Jeremy Michael} and Rubin, {Eric J.} and Betsy Russell and Russell, {David G.} and Sacchettini, {James C.} and Dirk Schnappinger and Michael Schrimpf and Upton, {Anna M.} and Peter Warner and Wyatt, {Paul Graham} and Ying Yuan",

year = "2021",

month = aug,

doi = "10.1038/s41591-021-01442-2",

language = "English",

volume = "27",

pages = "1333--1337",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

}

Aldridge, BB, Barros-Aguirre, D, Barry, CE, Bates, RH, Berthel, SJ, Boshoff, HI, Chibale, K, Chu, X-J, Cooper, CB, Dartois, V, Duncan, K, Fotouhi, N, Gusovsky, F, Hipskind, PA, Kempf, DJ, Lelièvre, J, Lenaerts, AJ, McNamara, CW, Mizrahi, V, Nathan, C, Olsen, DB, Parish, T, Petrassi, HM, Pym, A, Rhee, KY, Robertson, GT, Rock, JM, Rubin, EJ, Russell, B, Russell, DG, Sacchettini, JC, Schnappinger, D, Schrimpf, M, Upton, AM, Warner, P, Wyatt, PG & Yuan, Y 2021, 'The Tuberculosis Drug Accelerator at year 10: what have we learned?', Nature Medicine, vol. 27, pp. 1333-1337. https://doi.org/10.1038/s41591-021-01442-2

TY - JOUR

T1 - The Tuberculosis Drug Accelerator at year 10

T2 - what have we learned?

AU - Aldridge, Bree B.

AU - Barros-Aguirre, David

AU - Barry, Clifton E.

AU - Bates, Robert H.

AU - Berthel, Steven J.

AU - Boshoff, Helena I.

AU - Chibale, Kelly

AU - Chu, Xin-Jie

AU - Cooper, Christopher B.

AU - Dartois, Véronique

AU - Duncan, Ken

AU - Fotouhi, Nader

AU - Gusovsky, Fabian

AU - Hipskind, Philip A.

AU - Kempf, Dale J.

AU - Lelièvre, Joël

AU - Lenaerts, Anne J.

AU - McNamara, Case W.

AU - Mizrahi, Valerie

AU - Nathan, Carl

AU - Olsen, David B.

AU - Parish, Tanya

AU - Petrassi, H. Michael

AU - Pym, Alexander

AU - Rhee, Kyu Y.

AU - Robertson, Gregory T.

AU - Rock, Jeremy Michael

AU - Rubin, Eric J.

AU - Russell, Betsy

AU - Russell, David G.

AU - Sacchettini, James C.

AU - Schnappinger, Dirk

AU - Schrimpf, Michael

AU - Upton, Anna M.

AU - Warner, Peter

AU - Wyatt, Paul Graham

AU - Yuan, Ying

PY - 2021/8

Y1 - 2021/8

N2 - The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for the application of similar models to other diseases.

AB - The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for the application of similar models to other diseases.

KW - Bacterial infection

KW - Drug development

KW - Drug screening

KW - Intellectual-property rights

KW - Research management

UR - http://www.scopus.com/inward/record.url?scp=85109277736&partnerID=8YFLogxK

U2 - 10.1038/s41591-021-01442-2

DO - 10.1038/s41591-021-01442-2

M3 - Comment/debate

C2 - 34226736

VL - 27

SP - 1333

EP - 1337

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

ER -

The Tuberculosis Drug Accelerator at year 10: what have we learned?

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this